Unparalleled experience and perspective in real-world evidence

About Jeff

Jeff Trotter has enjoyed a diverse career in the healthcare industry spanning the past 30+ years.

As an entrepreneur, researcher, consultant, and innovator, Jeff was a pioneer in the health economics and outcomes research community and is an industry leader in the design and implementation of patient registries, observational studies, and other RWE (real-world evidence) initiatives.

Jeff founded Ovation Research Group, an internationally known research and consulting firm (acquired by ICON Clinical Research) and has been in executive management with other research organizations (ICON, PharmaNet and inVentiv Health). In 2014, Jeff co-founded Continuum Clinical, a professional services company including capabilities in Late-Stage Research, Patient Recruitment and Medical Communications. When Continuum’s Late-Stage Research business was acquired by Worldwide Clinical Trials in 2018, Jeff Trotter was named Senior Vice President – Worldwide Evidence. His adventure continues with the resumption of his independent consulting practice, J Trotter Research & Consulting.

He has spoken widely in front of varied industry audiences and has published over 75 original articles and research papers — including a book for the American Hospital Association, The Quest for Cost-Effectiveness in Healthcare: Achieving Clinical Excellence While Controlling Cost. Jeff is a founding member of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) and holds a Master of Management (MBA) degree from Northwestern University’s Kellogg School of Management and a Bachelor’s degree in Accounting from the University of Illinois.

Philosophy

The opportunity to leverage RWE — to address the unique needs of multiple stakeholders — has never been better than it is today. But capitalizing on the opportunity requires an in-depth understanding of the evolving life-sciences landscape, of strategic / scientific rationale, as well as the operational nuances “real world” research merits. The reality is that medical products are still approved under (controlled) conditions that are far different from the conditions under which they are actually used. And the processes for generating and/or accessing real-world data — and for informing targeted decision-makers — are far different from those employed in establishing and submitting evidence solely for regulatory approval.

Services

To support the full spectrum of clinical and commercial development — to more quickly bring innovative medical products to patients in need — J Trotter Research & Consulting (JTRC) can provide corporate- and/or project-based RWE / RWD expertise.

Our clients include:

Pharmaceutical companies
Biotech companies
Medical device companies
Contract research organizations
Technology vendors
Data (RWD) vendors
Private equity companies
Patient advocacy groups

Consulting Services

Advisory (Board / M&A) support
RWE planning
Organizational structure
Departmental support
Leadership / facilitation

Study-related services

RWE strategy and consensus development
Scientific (protocol development / review)
RWE / RWD operational planning
Resource / vendor management
Program support

Let us customize a win:win solution for you and your stakeholders.

Experience

A few of our favorite recent projects…

Supported the development of an integrated (real-world) evidence plan for a top-5 pharmaceutical company
Facilitated an interdepartmental consensus-building process to support the design and implementation of a global patient (disease) registry
Consulted with the Outsourcing department of a leading biotech company in RFP development, vendor selection, and operational requirements for RWE research
Provided on-going scientific advisory support to a medical device company and their technology vendor undertaking a global product registry
Coordinated the conceptual development, design, operational planning and on-going management of a 50,000-patient prospective observational study
Consulted with a top-20 pharmaceutical company on the development of an RWE Center of Excellence and creation of a Chief RWE Officer role
Provided consultative support to a technology company seeking to reposition their platform to support observational research
Served as Operating Advisor to a leading private-equity company investing in tech-support platforms for life-sciences research
Consulted for a leading commercial entity seeking to leverage consumer relationships in support of clinical trials and observational studies

Publications and presentations

Strand LN, Doane MJ, Arevalo C, McGrory JA, Weiden PJ, Achtyes ED, Harvey PD, Kane JM, Saklad SR, Trotter J, Velligan DI: Baseline Demographics and Clinical Characteristics From OASIS: Observational Study of Long-Acting Injectables in Schizophrenia: AMCP Annual Meeting, April 2024, New Orleans, LA
Strand LN, Doane MJ, Arevalo C, McGrory JA, Weiden PJ, Achtyes ED, Harvey PD, Kane JM, Saklad SR, Trotter J, Velligan DI: Treatment Patterns and Outcomes From OASIS: Observational Study of Long-Acting Injectables in Schizophrenia: AMCP Annual Meeting, April 2024, New Orleans, LA
Hariprasad SM, Trotter J, Arkin-Leydig K, Nguyen TH, Utzinger M, Addison J: Outcomes in nAMD following intravitreal anti-VEGF (reference and biosimilar): pilot study in American Academy of Ophthalmology IRIS (Intelligent Research in Sight) Registry Database; American Academy of Ophthalmology Annual Meeting, November, 2023, San Francisco, CA
Kilbane C, Drake R, Klepitskaya O, Serbin M, Jen E, Rattana S, Trotter J, Liang G; Improvements in Parkinson’s Disease Motor Complications After Treatment with Opicapone: Results from the OPTI-ON Study. International Congress of Parkinson’s Disease and Movement Disorders, August 2023, Copenhagen, Denmark.
LeWitt P, Klepitskaya O, Serbin M, Jen E, Rattana S, Trotter J, Liang G; Patient-Reported Improvements in “OFF”-Time Quality, Non-Motor Fluctuation Severity, and Medication Satisfaction in the Real-World OPTI-ON Study of Opicapone in Parkinson’s Disease; International Society for Pharmacoeconomics and Outcomes Research, May 2023, Boston, MA
LeWitt P, Klepitskaya O, Serbin M, Jen E, Rattana S, Trotter J, Liang G; Patient- Reported Improvement in Quality of “OFF” time, Severity of Non-Motor Fluctuations, and Medication Satisfaction in the OPTI-ON Study; American Academy of Neurology 2023 Annual Meeting, April, 2023, Boston, MA
Interview – The Evidence Base, April 2023
Haider B, O’Sullivan AK, Bessonova L, Keane E, Achtyes E, Harvey PD, Kane JM, Saklad SR, Trotter JP, Claxton A, Polak T, McGrory J, Noori W, Sikora Kessler A, Yarlas A, Velligan D. Changes in Clinical Management of Patients with Schizophrenia Treated with Long-Acting Injectable Antipsychotics (LAIs), Including Telepsychiatry Use, During the COVID-19 Pandemic. Neuropsychiatr Dis Treat. 2023 Mar 17;19:623-634.
Haider B, O’Sullivan A, Keane E, McGrory J, Strand LN, Achtyes ED, Harvey PD, Kane J, Saklad SR, Trotter JP, Velligan D; Observational Study of Long-Acting Injectables in Schizophrenia (OASIS): Baseline Patient Demographics and Clinical Characteristics of Early Enrollees; AMCP Annual Meeting, March 2023, San Antonio, TX
Goldman JG, Trotter JP, Larsen N, Doshi D, Rashid N, A Prospective Observational Study Examining the Real-World Clinical and Treatment Outcomes of Parkinson’s Disease Psychosis in the United States, NEI, November, 2022, Colorado Springs, CO
Bessonova L, Keane E, Achtyes E, Harvey PD, Kane JM, Saklad SR, Trotter JP, Claxton A, Hatfield T, McGrory J, Noori W, O’Sullivan AK, Biber JE, Sikora Kessler A, Yarlas A, Velligan DI, Clinical Management of Patients with Schizophrenia Treated with Long-Acting Injectable Antipsychotics and Telepsychiatry Use During COVID-19 Pandemic, Psych Congress, San Antonio, TX; Encore – NEI Congress, November 4-7, 2021, Colorado Springs, CO
Trotter JP, Khera A, Reviewing FDA’s Latest Guidance on RWD. Applied Clinical Trials 30.12 (2021): 40.
Rashid N, Ryan A, Heywood C, Trotter J, Alber V, Real-World Clinical, Treatment, and Patient Outcomes in Parkinson’s Disease Psychosis: Interim Year 2 Findings from the INSYTE Observational Study, AMCP Nexus 2020
Isaacson SH, Cummings JL, Fox SH, Trotter J, Larsen NJ, LoVerme J, Goldman JG, Examining Real-World Treatment Pathways and Outcomes in Parkinson’s Disease Psychosis: Early Findings from the INSYTE Observational Study, 2020 Pan American Parkinson’s Disease and Movement Disorders Congress (MDS-PAS)
Goldman JG, Fox SH, Coate B, LoVerme J, Trotter J, Shim A, Larsen NJ, Examining Real World Treatment Pathways in Parkinson Disease Psychosis: Initial Findings from the INSYTE Observational Study, 2019 Neuroscience Education Institute (NEI) Congress
Trotter JP, Real-World Evidence: An Opportunity and Responsibility – Strategic, Operational and Organizational Implications. Presented to Chiesi Pharmaceuticals Annual Meeting, Parma, Italy, August, 2019
Goldman JG, Fox SH, Isaacson S, Fredericks D, Trotter J, Healy K, Ryan A, Larsen NJ, Shim A, Examining Parkinson’s Disease Psychosis Treatment Outcomes in the Real World: Interim Year 1 Findings from the INSYTE Observational Study, 32nd Annual Symposium on the Etiology, Pathogenesis and Treatment of Parkinson Disease and Other Movement Disorders (PSG 2019)
Goldman J, Fredericks D, Trotter J, Heywood C, Ryan A, Block S, Rattana S, Shim A, Examining Parkinson’s Disease Psychosis Treatment Outcomes in the Real World: Preliminary Findings from the INSYTE Observational Study, (Barcelona, Spain) ISPOR 21st Annual European Congress 2018
Goldman J, Fredericks D, Trotter J, Heywood C, Ryan A, Shim A, Examining Parkinson’s Disease Psychosis Treatment Outcomes in the Real World: Preliminary Findings from the INSYTE Observational Study, (Hong Kong) International Congress of Parkinson’s Disease and Movement Disorders (MDS) 2018
Trotter JP, Middleton M, Kotapati S, Brokaw J, Gates C, Abernathy A: IMAGE: A “real world” multinational observational study in patients with advanced melanoma. Poster presentation – Society for Melanoma Research, Los Angeles, California, November 2012
Trotter JP, Results from Survey on Observational Research, 14th annual Meeting —International Society for Pharmacoeconomics and Outcomes Research: 2009 May; Orlando, Florida
Trotter, Jeffrey P. “Capturing Real World Data.” Applied Clinical Trials 19.9 (2010): 68.
Trotter JP, Avoiding the Gas-Guzzler: Eight Steps to More Productive Observational Studies, HealthEconomics.com Newsletter, April 2009
Trotter JP, Larson LR, Patient Registries — Short Course (instructor), 10th Annual Euro Meeting — ISPOR, 2007 October, Dublin, Ireland
The Brave New Real World: A Changing Paradigm for Documenting Product Value and Safety Post-approval, PharmaVoice podcast, August, 2007
Interview — Post-marketing Safety in the spotlight, September, 2007
Trotter JP, Patient Registries (moderator) special interest group, 9th Annual Euro Meeting — ISPOR, 2006 October, Copenhagen, Denmark
Trotter JP, Patient Registries Conference (chair) — 2003-2006, Orlando, Florida
Noe LL, Larson LR, Trotter JP, Utilizing Patient Registries to Support Health Economics Research: Integrating Observational Data with Economic Analyses, Models, and Other Applications, ISPOR Connections, October 2005
Interview — Patient Registries: Observations of the Real World, August, 2004
Trotter JP, Larson LR, Gordon MJ, Malamis P. The role of outcomes researchers in designing patient registries: Creating programs to meet broad organizational objectives. Proceedings of the Ninth Annual International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Meeting; 2004 May 16-19; Arlington, Virginia.
Becker RV, Burke TA, McCoy MA, Trotter JP, A model analysis of costs of blood pressure destabilization and edema associated with rofecoxib and celecoxib among older patients with osteoarthritis and hypertension in a Medicare choice population, ClinTher, 2003: 24, 2: 647-662
Trotter JP. Patient registries: A new gold standard for “real world” research. The Ochsner Journal. 2002;4(4):211-4.
Sullivan DH, Morley JE, Johnson LE, Barber A, Olson JS, Stevens MR, Yamashita BD, Reinhart SP, Trotter JP, Olave XE. The GAIN (Geriatric Anorexia Nutrition) Registry: The impact of appetite and weight on mortality in a long-term care population. J Nutr Health Aging. 2002; 6(4):275-81.
Becker RV, Noe LL, Trotter JP and Williamson TE. A cost-effective comparison of extended-release tolterodine (Detrol LA) versus controlled-release oxybutynin (Ditropan XL). Proceedings of the South Central Section of the American Urological Association Annual Conference; 2001 Sep; Austin, Texas.
Becker RV, Burke T, Williamson T, Trotter JP. An economic evaluation of the cost of edema and systolic blood pressure destabilization in cox-2-treated patients with osteoarthritis and hypertension. Value Health. 2001 Nov-Dec;4(6):485.
Lichtenstein GR, Keenan G, Chen DM, Shakur UM, Trotter JP. Crohn’s disease severity and treatment: Impact on IBDQ scores. Am J Gastroenterol. 2001 Sep;96(9 Suppl):S298.
Healey M, Deverka P, Fox S, Gondek K, Edelman-Lewis B, Lydick E, Singh G, Temple R, Trotter JP, Methodological Issues in Pharmacoeconomic Evaluations — Clinical Studies, Value in Health, November, 2000
Sandborn WJ, Feagan BG, Hanauer SB, Lichtenstein GR, Salzberg B, Hyams J, Schaible T, Vreeland MG, Larson LR, Trotter JP, Mummert LH, and Chen DM. TREAT registry results: Correlations between physician assessments of disease severity and IBDQ in Crohn’s disease patients. Proceedings of the American College of Gastroenterology (ACG) Annual Conference; 2000 Oct; New York, New York.
Sandborn WJ, Lichtenstein GR, Feagan BG, Hanauer SB, Hyams J, Salzberg B, Schaible T, Vreeland MG, Larson LR, Mummert LH, Trotter JP. Long-term impact of Crohn’s disease pharmacotherapy: TREAT registry baseline results. Presented at Capri 2000: International Meeting on Inflammatory Bowel Diseases; 2000 Jun; Capri, Italy
Trotter, J.P.: The Cost-effectiveness of Tamoxifen in the Prevention of Breast Cancer. Safeguarding the Health of Women at High Risk for Breast Cancer – Seminar sponsored by Zeneca Pharmaceuticals, Las Vegas, March, 1999.
Trotter, J.P.: Health Economic Considerations in HIV Treatment. In Advances in the Management of Human Immunodeficiency Virus Infection: Implications for Managed Care. Supplement to Managed Care Interface, March, 1999.
Trotter, J.P.: Torsemide: Pharmacoeconomic Research in the United States. International Press Conference sponsored by Boehringer Mannheim Pharmaceuticals, Palma de Mallorca, May, 1997.
Pleil AM, Francis CW, Reinhart SP, Trotter JP: A Prospective Pharmacoeconomic Evaluation of Fragmin (dalteparin) in Total Hip Replacement Surgery. American Pharmaceutical Association 144th Annual Meeting, Los Angeles, March, 1997.
Heaton AH, Trotter JP: A Pharmacoeconomic Assessment of Torsemide in the Treatment of Congestive Heart Failure. American Journal of Managed Care, Nov/Dec,1996.
Noe LL, Heaton A, Simons R, Haim M, Trotter JP: The Treatment of Rheumatoid Arthritis in Managed Care: A Pharmacoeconomic Assessment. American College of Rheumatology 60th National Scientific Meeting, Orlando, Florida, October, 1996.
Trotter, J.P.: Conducting Naturalistic Pharmacoeconomic Research in Managed Care. Pharmacoeconomics and Quality of Life Symposium, Philadelphia, September, 1996.
Larson, L, Ortmeier, B, Trotter, JP: Pharmacoeconomics in Behavioral Health Care. Behavioral Health Management, January, 1996.
Heaton A, Bryant J, Berman B, Trotter JP: A Pharmacoeconomic Comparison of Loop Diuretics in the Treatment of Congestive Heart Failure. Medical Interface, January, 1996.
Trotter, J.P.: The Pharmacoeconomics of Congestive Heart Failure. National Managed Healthcare Congress West, San Diego, January, 1996.
Trotter, J.P.: The Pharmacoeconomics of Congestive Heart Failure. Cardiovascular Disease Management seminar, Palm Beach, Florida, December, 1995.
Carter, J.C., Trotter, J.P.: The Use of GnRH Analogs in the Treatment of Endometriosis. The Female Patient, December, 1995.
Trotter, J.P.: The Pharmacoeconomics of Congestive Heart Failure. The Academy of Managed Care Pharmacy, Washington, DC, November, 1995.
Reinhart, S.R., Trotter, J.P., Larson, L.R.: A Pharmacoeconomic Comparison of Narcotic and Non-Narcotic Analgesics. P&T, October, 1995.
Trotter, J.P.: The Pharmacoeconomics of Congestive Heart Failure. The Midwest Managed Healthcare Congress, Chicago, September, 1995.
Trotter, J.P.: Cost-Effective Decision Model for Congestive Heart Failure. Boehringer Mannheim symposium at the Annual Meeting for the Academy of Managed Care Pharmacy, Toronto, May, 1995.
Larson, L.R., Trotter, J.P.: The Continuing Evolution of Pharmacoeconomics. Product Management Today, April, 1995.
Trotter, J.P., Glasser, M.S.: Alternative Approaches to Hysterectomy: Clinical and Economic Implications for Managed Care. Medical Interface, March, 1995.
Trotter, J.P.: The Quest for Cost-Effectiveness in Healthcare: Achieving Clinical Excellence While Controlling Costs, American Hospital Publishing Co., division of the American Hospital Association, Chicago, February 1995.
Trotter, J.P.: The ABCs of Cost-Effectiveness. Materials Management, January, 1995.
Interview – Managed Care Update, January, 1995.
Faculty – Managing Prescribing Outcomes. Teleconference sponsored by The Vanderveer Group., January, 1995.
Trotter, J.P.: Pharmacoeconomics in the Managed Care Environment. Presented at Outcomes Training program for Astra/Merck Group, Philadelphia, October, 1994.
Trotter, J.P.: Pharmacy, the P&T Committee, and Outcomes Research. Annual SunHealth Alliance CEO/Department Managers Meeting, Amelia Island, Florida, September, 1994.
Faculty – Pharmacoeconomics: Uniting for Successful Outcomes. Distributed by Zeneca Pharmaceutical Group, September, 1994.
Moderator – Roundtable Discussion. GnRH Agonists for the Treatment of Endometriosis: Implications for Managed Care. Supplement to Medical Interface, August, 1994.
Trotter, J.P.: Introduction. GnRH Agonists for the Treatment of Endometriosis: Implications for Managed Care. Supplement to Medical Interface, August, 1994.
Trotter, J.P.: Introduction. GnRH Agonists for the Treatment of Advanced Prostate Cancer: Managed Care Implications. Supplement to Medical Interface, July, 1994.
Moderator – Roundtable Discussion. GnRH Agonists for the Treatment of Advanced Prostate Cancer: Managed Care Implications. Supplement to Medical Interface, July, 1994.
Trotter, J.P.: Conducting Outcomes Studies. The Prudential Outcomes Forum. Presented at the Academy of Managed Care Pharmacy annual meeting, Boston, May, 1994.
Trotter, J.P.: The Strategic Approach to Health Economics. Pharmacoeconomics workshop, Philadelphia, March, 1994.
Trotter, J.P.: The Strategic Approach to Health Economics. Presented at the Medical Surgical Marketing Research Group spring meeting. New Orleans, March, 1994.
Trotter, J.P.: Using Outcomes Data in Quality Management. Presented at Managed Care educational program sponsored by CIBA-GEIGY, Ft. Lauderdale, March, 1994
Trotter, J.P.: The Strategic Approach to Health Economics. American Pharmaceutical Product Managers Associates conference, Philadelphia, January, 1994.
Healthcare Reform. WJJD-AM Radio: Your Health Matters, December, 1993.
Trotter, J.P., Reinhart, S.P., Katz, R.M., Glazier, H.S.: Economic Assessment of Ketorolac Versus Narcotic Analgesics in Postoperative Pain Management. Clinical Therapeutics, September/October, 1993.
Reinhart, S.P., Trotter, J.P.: An Economic Assessment of Ofloxacin. Drugs, 45 (Suppl 3): 465-466, 1993.
Trotter, J.P.: Maximizing the Marketing Value of Pharmacoeconomics. Seminar on Profiting in the Managed Care Marketplace, Philadelphia, July, 1993.
Colwell, J.C., Foreman, M.D., Trotter, J.P.: A Comparison of the Efficacy and Cost–Effectiveness of Two Methods of Managing Pressure Sores. Decubitus, July 1993.
Roundtable Discussion. The Implications of Nonsedating Antihistamines on Managed Care. Supplement to Medical Interface, June, 1993.
Trotter, J.P., Glazier, H.S., Larson, L.R., Thompson, K.A., Giles, T.D.: The Treatment of Allergic Rhinitis: An Economic Analysis. Supplement to Medical Interface, June, 1993.
Trotter, J.P.: The Evolution of Health Economics. Product Management Today, April, 1993.
Johnson, N.E., Trotter, J.P.: Health Economics. Workshop at American Pharmaceutical Product Managers Associates conference, Fairfield, New Jersey, February, 1993.
Creating a New Paradigm for Cost-Effectiveness Research. Pharmaceutical Outcomes News, January 1993.
Trotter, J.P.: Effective Product Marketing with Efficient Use of Outcomes Research Data. Seminar on Outcomes Research, Philadelphia, October, 1992.
Reinhart, S.P., Trotter, J.P.: Incorporating Economic Analysis into Clinical Trials. Applied Clinical Trials, September, 1992.
Trotter, J.P.: 4th International Symposium on New Quinolones. Poster presentation. An Economic Assessment of Ofloxacin, Munich, Germany, August, 1992.
Trotter, J.P.: Promotional Strategies Featuring Outcomes Research. Seminar on Pharmaceutical Promotions: New Targets, New Messages, New York City, July, 1992.
Trotter, J.P.: Industry Must Help Establish Standards in Health Economics. Pharmaceutical Executive, July, 1992.
Trotter, J.P.: Pharmacy, the P & T Committee, and Outcomes Research. Presented to Hospital Shared Services Association of the State of Washington – Sponsored by Roche Laboratories, Winthrop, Washington, June, 1992.
Trotter, J.P.: Using Outcomes Research in Pricing Decisions. Fifth Annual Pricing Institute, Chicago, Illinois, April, 1992.
Trotter, J.P.: In Support of Cost Effectiveness as a Criterion for Medical Coverage. Medical Interface, January, 1992.
Trotter, J.P.: Problems and Potentials of Outcomes Research as a Marketing Vehicle. Cost Effectiveness/Outcomes Research Training Seminar at Boehringer-Ingelheim Pharmaceuticals, Danbury, Connecticut, September, 1991.
Trotter, J.P.: Cost Effective Technology in Managed Care. The Managed Health Care Congress Midwest, Chicago, September, 1991.
First annual conference on Therapeutic Cost Effectiveness. Pharmaceutical Executive, September, 1991 – February, 1992
Cost-effectiveness of pharmaceuticals a subject of new quarterly report. Pharmaceutical Representative, October, 1991.
Consumer Reports, Medical Style. Hospital Purchasing News, July 1991.
Trotter, J.P.: Maximizing the Effectiveness of Cost Effectiveness in Pharmaceutical Marketing. Seminar on Challenges and Opportunities in Pharmaceutical Marketing, New York City, June, 1991.
Moderator/Panelist: The Impact of Technology on Managed Care: The National Managed Health Care Congress, Washington, D.C., April, 1991.
Panelist: Twenty-Fourth Annual Mary Kelly Mullane Clinical Nursing Symposium: Current Issues in Nursing: Health Care Policy and Nursing Practice: The Impact of Technology on Nursing, Chicago, March, 1991.
New report looks at product cost effectiveness. Hospitals Magazine, March, 1991.
Trotter, J.P.: The Financial Implications of Aggressive Skin Care. Presented at Health Care 1990: Financial and Clinical Considerations conference sponsored by Support Systems International, Bridgeport, Connecticut, November, 1990.
Economics and the Pharmacy. Hospitals Magazine, October, 1990.
Trotter, J.P., Colwell, J.: Management of Pressure Sores: A Cost Effectiveness Analysis of DuoDerm CGF Compared to Moist Saline Dressings — Preliminary Results. Presented at the ConvaTec National Sales Meeting, Scottsdale, Arizona, May, 1990.
Trotter, J.P.: Outside Consultants in Pharmacy: A Consultant’s Perspective. Presented at the Illinois Council of Hospital Pharmacists Annual Meeting, Chicago, Illinois, April, 1990.
Trotter, J.P.: The Economics of Preventive Healthcare. Presented at Medical Education Program sponsored by Merck, Sharpe & Dohme, Greenville, North Carolina, March, 1990.
Trotter, J.P.: Pharmacy Must be an Equal Player in Health Care. American Druggist, March, 1990.
Trotter, J.P.: Maximizing the Effectiveness of Cost Effectiveness. Medical Interface, February, 1990.
Trotter, J.P.: Understanding the Economic Buyer. Presented to Baxter Scientific Products National Sales Meeting, Phoenix, Arizona, January, 1990.
Trotter, S.A., Trotter, J.P.: What’s Wrong With This Idea. An Open Letter to the Health Insurance Industry. Nursing Homes, November-December, 1989.
Hospitals Look for Savings in Unusual Places. Hospitals Magazine, December, 1989.
Biotechnology, Cost Concerns Dominate in 1989. Hospitals Magazine, December, 1989.
Roundtable Discussion. The Economic Effects of Misoprostol to Prevent Gastric Ulcers in Patients. Supplement to Medical Interface, November, 1989.
Trotter, J.P.: Introduction: A Roundtable Discussion on the Economic Effects of Misoprostol to Prevent Gastric Ulcer in Patients. Medical Interface, November, 1989.
Trotter, J.P.: The Impact of Health Economics on Pharmacists. Keynote address for the Sixth Annual ICI Pharmaceuticals/American Druggist Symposium, San Diego, California, October, 1989.
Kirk, 0., Sullivan, D., Trotter, J.P.: Marketing Nursing Home Cost Effectiveness to Third-Party Payors. Presented at the American Health Care Association Annual Convention, New Orleans, Louisiana, October, 1989.
Harris, K.A., Trotter, J.P.: Selling to Provider Top Management. Presented at the Health Industry Distributers Association Annual Convention, Chicago, Illinois, September, 1989.
Trotter, J.P.: Cost Effectiveness: Marketplace Applications. Presented to Sandoz Pharmaceuticals Corp., East Hanover, New Jersey, June, 1989.
Trotter, J.P.: Marketing to the Managed Care Executive. Pharmaceutical Executive, June, 1989.
Trotter, J.P.: Preparing for the Next Decade, Today. Health Industry Today, December, 1988.
Trotter, J.P.: Strategic Cost Management. Trustee Magazine, July, 1988.
Herr, J., Trotter, J.P., Harris, K.A.: Selling from Strength: Cost Management and Cost Effectiveness in Medical Products Supply and Patient Care. Presented to the Health Industry Distributors Association Educational Foundation, Tampa, Florida, May, 1988.
Trotter, J.P.: Cost Effectiveness in Health Care Today. Presented to C.R. Bard, Inc. Annual Executive Management Meeting, Hamilton, Bermuda, May, 1988.
Medical Records Briefing, March, 1988.
Trotter, J.P.: Cost Effectiveness in Health Care Today. Presented to Eli Lilly & Co. National Hospital Pharmacy Advisory Board, at American Society of Hospital Pharmacists Annual Meeting, Atlanta, Georgia, December, 1987.
Trotter, J.P.: Reimbursement and Cost Effectiveness. Presented to Kendall Co., Boston, Massachusetts, October, 1987.
Trotter, J.P.: Cost Effectiveness Studies: Rationale, Methodology & Operation. Presented to G.D. Searle & Co. Marketing and Clinical Research sections, Skokie, Illinois, September, 1987.
Trotter, J.P.: Cost Effectiveness in Health Care Today. Presented to the American Hospital Association, Society for Hospital Risk Management Annual Meeting, Chicago, Illinois, September, 1987.
Trotter, J.P.: Cost Effectiveness: The Vendor’s Role in the Delivery of Quality Healthcare – A “win-win-win” Situation. Health Industry Today, September, 1987.
Latest Report on Cost Effective Products and Technologies Available. Health Industry Today, May, 1987.
Trotter, J.P.: Innovative Management Information Systems. Paper presented at the National Association for Home Care Annual Meeting, New Orleans, Louisiana, February, 1987.
Trotter, J.P., Hillman, L.: Cost Effective Products Help Preserve Quality, Boost Profits. Modern Healthcare, February, 1987.
New Report will offer Hospitals a Guide to Product Cost Effectiveness. Health Industry Today, January, 1987.
Report Capitalizes on Industry Need for Analysis of Cost Effective Claims. Modern Healthcare, September, 1986.
Trotter, J.P., Burik, D.: Hospital and Medical Staff Joint Ventures. Presented to the Illinois Hospital Association, Oak Brook, Illinois, January, 1986.
Trotter, J.P., Feller, J.: Entrepreneurial Business Planning. Presented at the National Association for Home Care Annual Meeting, Las Vegas, Nevada, October, 1985.
Trotter, J.P.: The Entrepreneur’s Approach to Business Planning. Caring Magazine, October, 1985.
Trotter, J.P.: Entrepreneurial Business Planning. Journal of Anesthesiology, October, 1985.
Trotter, J.P.: Designing an Effective Management Information System. Presented at National Management Institute, Chicago, Illinois, May, 1985.
Trotter, J.P.: Receivables Management/Uniform Billing. Presented at the National Association for Home Care Annual Meeting, Boston, Massachusetts, October, 1984.
Trotter, J.P.: Strategies in View of PPS. Presented at the Ohio Hospital Association Annual Meeting, Columbus, Ohio, September, 1984.
Trotter, J.P.: The Prospective Payment System. Impact on Non-Revenue Producing Departments. Presented at the New England Society for Hospital Management Engineers Annual Meeting, Sebasco Estates, Maine, September, 1984.
Trotter, J.P.: The Prospective Payment System. Presented to the American Hospital Association, Society for Hospital Biomedical Engineering Annual Meeting, San Diego, California, May, 1984.
Trotter, J.P., Burik, D.: The Power and Use of Data in Cost Containment. Presented at the CAS User’s Group Annual Meeting, Orlando, Florida, May, 1982.

Contact

Let’s work together.

Email

jeff@jtrotresearch.com